September 20, 2026 4:02 PM ET
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Chumi Khurana, senior vice president of U.S. Oncology
NASDAQ:JAZZ